Certificate PL-26-00273 · Prostamax 20 mg Pen · lot PL-2610-158
VerifyCertificate page
PrymaLab
PrymaLab
PrymaLab Analytical · In-house laboratory
3705 Music Branch Rd, Ashland, KY 41102 · +1 (606) 465-9063 · prymalab.net
Certificate no.
PL-26-00273
Verification key
6BGS5DM3
Scan or enter both at
prymalab.net/testing/verify

Certificate of Analysis · Lot release

Prostamax 20 mg Pen

Lot PL-2610-158 · Solution · Label claim 20 mg/mL
Tested in-house by PrymaLab
In-house analytical result,
not an independent third-party test
Lot / batch number
PL-2610-158
Date made
2026-10-06
Date of analysis
2026-10-07
Date issued
2026-10-21
Retest / expiry
2028-10-06
Units in lot / sampled
213 / 3
Storage
—
Certificate type
Lot COA, 2 pages
Compound
Prostamax
Lys-Glu-Asp-Pro (KEDP); Khavinson prostate peptide bioregulator
CAS number
n/a
Molecular formula
C20H33N5O9
Theoretical mass (avg.)
487.50 Da
Sequence
KEDP
Purity · RP-HPLC, area %
99.71%
Specification ≥ 99.0% • main peak at 10.57 min
Identity · Observed Mass
487.52 Da
Theoretical 487.50 Da • +0.02 Da (41 ppm)
Overall conclusion
PASS
Meets every specification for the tests performed
TestMethodSpecificationResultConclusion
Identity (mass)LC-MS, ESI positiveTheoretical ± 1.0 Da487.52 DaPASS
PurityRP-HPLC, UV 214 nm, area%≥ 99.0%99.71%PASS
Largest impurityRP-HPLC, area%≤ 1.0%0.17% (RT 11.50)PASS
Assay (label claim)Assay vs label claim19–21 mg/mL20.40 mg/mLPASS
Bacterial endotoxinLAL, kinetic≤ 5.0 EU/mg0.052 EU/mgPASS
SterilityUSP <71>, 14-dayNo growthNo growthPASS

1HPLC chromatogram

Data file: PL-2610-158-HPLC.raw · Column C18, 150 × 4.6 mm · UV 214 nm
0.01%0.1%1%10%100%891011121314Retention time (min) · stick height = area % (log scale)99.71% · 10.57 min0.06% †0.17% †0.06% †
Peak plot drawn from the integrated peak table (area %, log scale); it is not the instrument trace, which is retained in PL-2610-158-HPLC.raw. † Nominal reference retention time for the assigned impurity; the main-peak RT is observed in this lot.
PrymaLab
PrymaLab
Certificate of Analysis · continued
Prostamax 20 mg Pen · Lot PL-2610-158 · Certificate PL-26-00273
Lot PL-2610-158
Method, peak table and approval

2HPLC method · PL-2610-158-HPLC.raw

Instrument
Waters Alliance e2695
Data System
Empower 3
Detector
UV absorbance
Detection Wavelength
214 nm
Column
C18, 150 × 4.6 mm, 3.5 µm
Mobile Phase A
0.1% TFA in water
Mobile Phase B
0.1% TFA in MeCN
Gradient
5–95% B over 25 min (linear)
Flow Rate
1.0 mL/min
Column Temperature
40 °C
Injection Volume
10 µL

3Gradient program

Time (min)% A% B
0.0955
25.0595

4Peak table

PeakRT (min)AreaArea %
19.30 †—0.06
210.57—99.71
311.50 †—0.17
412.10 †—0.06
Total—100.00
Peaks: 1 deamidation product; 2 main peak (Prostamax); 3 isoaspartate (isoasp) variant; 4 truncated sequence · Area % from the integrated peak table (absolute areas are not part of the lot-release export) · † nominal reference RT for the assigned impurity · Purity = main peak area ÷ total integrated area × 100, to two decimals; main peak shaded.

5Identity by mass spectrometry

Instrument
Waters SQD
Ionization / Mode
ESI, positive
Reference m/z (charge)
488.51 (M+H)+
Deconvoluted Mass
487.52 Da
Theoretical Mass
487.50 Da
Difference
+0.02 Da (41 ppm)
Data File
PL-2610-158-MS.d
Acceptance
Within ± 1.0 Da

6Additional tests

TestPerformed byDateReport / file
Assay vs label claimPrymaLab Analytical2026-10-07—
Endotoxin (LAL, kinetic)PrymaLab Analytical2026-10-07—
Sterility (USP <71>, day-14 read-out)PrymaLab Analytical2026-10-21—
A test with no row here was not performed on this lot. Outside-laboratory reports, when used, are attached and named below.

7Review and approval

D. Reynolds
Analyst · performed the testing
Date: 2026-10-21
S. Calloway
Reviewer · checked against raw data
Date: 2026-10-21
M. Phelps
Lab Director · approved for release
Date: 2026-10-21